These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36455147)

  • 1. Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Aggarwal C; Saba NF; Algazi A; Sukari A; Seiwert TY; Haigentz M; Porosnicu M; Bonomi M; Boyer J; Esser MT; Cheng LI; Agrawal S; Jennings EC; Durham NM; Fraser K; Lissa D; Gong M; Ceaicovscaia N; Gascó Hernández A; Kumar R
    Clin Cancer Res; 2023 Feb; 29(3):560-570. PubMed ID: 36455147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.
    Morris VK; Jazaeri A; Westin SN; Pettaway C; George S; Huey RW; Grinsfelder M; Shafer A; Johnson B; Vining D; Guo M; Fellman B; Frumovitz M
    Oncologist; 2023 Jul; 28(7):618-623. PubMed ID: 37104874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.
    Algazi A; Papadopoulos KP; Tsai F; Hansen AR; Angra N; Das M; Sheth S; Siu LL
    ESMO Open; 2024 Aug; 9(8):103646. PubMed ID: 39043009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
    Segal NH; Ou SI; Balmanoukian A; Fury MG; Massarelli E; Brahmer JR; Weiss J; Schöffski P; Antonia SJ; Massard C; Zandberg DP; Khleif SN; Xiao F; Rebelatto MC; Steele KE; Robbins PB; Angra N; Song X; Abdullah S; Butler M
    Eur J Cancer; 2019 Mar; 109():154-161. PubMed ID: 30731276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
    Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
    Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
    Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
    Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Park R; Li J; Slebos RJC; Chaudhary R; Poole MI; Ferraris C; Farinhas J; Hernandez-Prera J; Kirtane K; Teer JK; Song X; Hall MS; Tasoulas J; Amelio AL; Chung CH
    Oral Oncol; 2024 Jul; 154():106866. PubMed ID: 38820888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Kim H; Park S; Jung HA; Lee SH; Park K; Ahn YC; Oh D; Ahn MJ
    Cancer Res Treat; 2023 Oct; 55(4):1104-1112. PubMed ID: 37202212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
    Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
    Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
    Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
    Seiwert TY; Wildsmith S; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Baker V; Evans B; Morsli N; Jill Walker ; Real K; L'Hernault A; Psyrri A
    Cancer Immunol Immunother; 2024 Mar; 73(4):70. PubMed ID: 38430375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
    Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
    J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.